Publications by authors named "Peter Auguste"

Claim this Profile
E
Effectiveness and Safety of Nusinersen and Risdiplam in Spinal Muscular Atrophy: A Systematic Review.
Amin Mehrabian, Peter Auguste, Amy Grove, Anna Brown, Janette Parr

Ann Clin Transl Neurol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic evaluations of disease-modifying therapies for spinal muscular atrophy: a systematic literature review.
Mehdi Yousefi, Amin Mehrabian, Anna Brown, Furqan Butt, Jeremiah Donoghue, Peter Auguste

Orphanet J Rare Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges of using and managing medication: a meta-ethnography of the experiences and perceptions of people with intellectual disability and people who support them.
Iman Ghosh, Danielle Adams, Peter Auguste, Anna Brown, Eddie Chaplin

BMJ Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Software with artificial intelligence-derived algorithms for detecting and analysing lung nodules in CT scans: systematic review and economic evaluation.
Julia Geppert, Peter Auguste, Asra Asgharzadeh, Hesam Ghiasvand, Mubarak Patel

Health Technol Assess· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of excluding children with Shiga toxin-producing (STEC) from childcare settings until microbiological clearance compared to return to childcare settings before microbiological clearance.
Dana Šumilo, Peter Auguste, Claire Jenkins, Jason Madan, Noel D McCarthy

Epidemiol Infect· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of percutaneous mitral repair for patients with severe secondary mitral regurgitation: an updated evaluation using a modelling approach based on COAPT final data after 5-year follow-up.
Martin Connock, Peter Auguste, Jean-François Obadia, Xavier Armoiry

BMJ Open· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Software using artificial intelligence for nodule and cancer detection in CT lung cancer screening: systematic review of test accuracy studies.
Julia Geppert, Asra Asgharzadeh, Anna Brown, Chris Stinton, Emma J Helm, Peter Auguste

Thorax· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence software for analysing chest X-ray images to identify suspected lung cancer: an evidence synthesis early value assessment.
Jill Colquitt, Mary Jordan, Rachel Court, Emma Loveman, Janette Parr, Peter Auguste

Health Technol Assess· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOUND Trial: randomised controlled trial study protocol for case finding of obstructive sleep apnoea in primary care using a novel device.
Michelle A Miller, Ly-Mee Yu, Asad Ali, Patricia Apenteng, Peter Auguste

BMJ Open· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential impact on cost-effectiveness estimates of using immature survival data: a case study based on transcatheter edge-to-edge repair (TEER) used for patients with severe mitral regurgitation at high surgical risk.
Martin Connock, Peter Auguste, Aude Capelle, Anna-Maria Hénaine, Jean-François Obadia

BMJ Open· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of updated trial data on the cost-effectiveness of percutaneous mitral repair.
Martin Connock, Peter Auguste, Jean-François Obadia, Lazaros Andronis, Xavier Armoiry

PLoS One· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the assumption of waning of treatment effect applied consistently across NICE technology appraisals? A case-study focusing on disease-modifying therapies for treatment of multiple sclerosis.
Xavier Armoiry, Xia Wang-Steverding, Martin Connock, Amy Grove, Aileen Clarke, Peter Auguste

Int J Technol Assess Health Care· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of testing for latent tuberculosis infection in people with HIV.
Peter E Auguste, Hema Mistry, Noel D McCarthy, Paul A Sutcliffe, Aileen E Clarke

AIDS· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
Chris Stinton, Mary Jordan, Hannah Fraser, Peter Auguste, Rachel Court

Health Technol Assess· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of community health systems strengthening: quality improvement interventions at community level to realise maternal and child health gains in Kenya.
Meghan Bruce Kumar, Jason J Madan, Peter Auguste, Miriam Taegtmeyer, Lilian Otiso

BMJ Glob Health· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme.
Martin Connock, Peter Auguste, Xavier Armoiry

Eur J Health Econ· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conflicting findings between the Mitra-Fr and the Coapt trials: Implications regarding the cost-effectiveness of percutaneous repair for heart failure patients with severe secondary mitral regurgitation.
Xavier Armoiry, Jean-François Obadia, Peter Auguste, Martin Connock

PLoS One· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective.
Martin Connock, Lazaros Andronis, Peter Auguste, Claude Dussart, Xavier Armoiry

Expert Opin Biol Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Peter Auguste, Jill Colquitt, Martin Connock, Emma Loveman, Rachel Court

Pharmacoeconomics· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.
Daniel Gallacher, Peter Auguste, Pamela Royle, Hema Mistry, Xavier Armoiry

Clin Drug Investig· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.
Martin Connock, Peter Auguste, Claude Dussart, Jacques Guyotat, Xavier Armoiry

J Neurooncol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Daniel Gallacher, Xavier Armoiry, Peter Auguste, Rachel Court, Theodoros Mantopoulos

Pharmacoeconomics· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
Daniel Gallacher, Peter Auguste, Martin Connock

Int J Technol Assess Health Care· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness of beta-interferons and glatiramer acetate for relapsing-remitting multiple sclerosis: systematic review and network meta-analysis of trials including recommended dosages.
G J Melendez-Torres, Xavier Armoiry, Rachel Court, Jacoby Patterson, Alan Kan, Peter Auguste

BMC Neurol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetic retinopathy and the use of laser photocoagulation: is it cost-effective to treat early?
Hema Mistry, Peter Auguste, Noemi Lois, Norman Waugh

BMJ Open Ophthalmol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis